Latest Cancer Diagnostics News

Page 1 of 12
Pacific Edge has secured final Medicare coverage for Cxbladder Triage and Triage Plus in intermediate-risk microhematuria, with the policy due to take effect on 20 December. The decision gives the company a clearer reimbursement pathway, but revenue gains still depend on adoption and testing volumes.
Ada Torres
Ada Torres
6 Nov 2026
INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
Ada Torres
Ada Torres
29 Oct 2026
Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.
Ada Torres
Ada Torres
19 Oct 2026
Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
Victor Sage
Victor Sage
29 Sept 2026
Cleo Diagnostics has begun developing a multi-biomarker blood test for ovarian cancer screening in asymptomatic women, targeting a stated $150 billion global market. The prototype program will run alongside the company’s pre-surgical test, with initial proof-of-concept data expected early next quarter.
Victor Sage
Victor Sage
24 Sept 2026
Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.
Ada Torres
Ada Torres
22 Sept 2026
Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.
Victor Sage
Victor Sage
14 Sept 2026
BCAL Diagnostics has increased its shareholding in Genetic Signatures to nearly a fifth, aiming to leverage infectious disease technology to complement its cancer detection portfolio.
Ada Torres
Ada Torres
26 Aug 2026
Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.
Ada Torres
Ada Torres
20 Aug 2026
BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.
Ada Torres
Ada Torres
30 July 2026
Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.
Ada Torres
Ada Torres
21 July 2026
INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.
Ada Torres
Ada Torres
14 July 2026

Browse the archive

Full archive